Large scale manufacturing of B43(anti-CD19)-Genistein for clinical trials in leukemia and lymphoma

被引：9

作者：

Myers, DE ^{[1
]}

Sicheneder, A ^{[1
]}

Clementson, D ^{[1
]}

Dvorak, N ^{[1
]}

Venkatachalam, T ^{[1
]}

Sev, AR ^{[1
]}

Chandan-Langlie, M ^{[1
]}

Uckun, FM ^{[1
]}

机构：

[1] Wayne Hughes Inst, St Paul, MN USA

来源：

LEUKEMIA & LYMPHOMA | 1998年 / 29卷 / 3-4期

关键词：

large scale manufacturing B43 (anti-CD19)-genistein; clinical trials; leukemia & lymphoma;

D O I：

10.3109/10428199809068569

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We have conjugated the murine monoclonal anti-CD19 antibody B43 to the tyrosine kinase inhibitor genistein to construct an effective immunoconjugate against CD19 antigen positive hematologic malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted the manufacturing of a highly purified clinical-grade B43-Genistein preparation. In clonogenic assays, B43-Genistein elicited selective and potent cytotoxicity against CD19 antigen positive human leukemia cells. To our knowledge, this work represents the first effort of producing a clinical-grade genistein immunoconjugate for treatment of B-lineage leukemia and lymphoma.

引用

页码：329 / +

页数：11

共 7 条

[1] MEMBRANE-ASSOCIATED CD19-LYN COMPLEX IS AN ENDOGENOUS P53-INDEPENDENT AND BCL-2-INDEPENDENT REGULATOR OF APOPTOSIS IN HUMAN B-LINEAGE LYMPHOMA-CELLS [J].